Treatment of coagulation disease by administration of recombinant vwf

FIELD: medicine.

SUBSTANCE: group of inventions relates to a method of treating von Willebrand's disease or hemophilia A in a patient in need of treatment comprising administering to the patient a recombinant vWF (vWF) factor so that the half-life of factor VIII is prolonged compared to a patient administered vWF derived from blood plasma, where pFB is not modified with an aqueous soluble polymer. In this case, the pFB is a composition of high molecular weight PV multimers containing at least 20% of the PV emperors or higher-order multimers, with the rVB having a higher specific activity than the vWF derived from the blood plasma. The group of inventions also relates to a method for treating hemophilia A or vWF in a patient in need of treatment that includes administering to the patient a recombinant vWF (vWF) factor, wherein the half-life of FVIII is at least 1.5 times higher than the half-life of FVIII in the patient being treated Von Willebrand factor derived from blood plasma.

EFFECT: increase in the half-life of FVIII in the treatment of von Willebrand disease or haemophilia A in the subject.

29 cl, 5 ex, 22 dwg, 34 tbl

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a medical absorbable haemostatic and wound healing material for osteal wounds and a method for producing it. The absorbable haemostatic material for osteal wounds contains 40-95% of a primary material and 5-60% of an auxiliary on the basis of weight percentage, wherein the primary material contains an oligosaccharide, a polysaccharide or a mixture of the oligosaccharide and polysaccharide, while the auxiliary contains (1) one or more polyatomic alcohols, (2) one or more emulsifiers. The method for producing the absorbable haemostatic and wound healing material for osteal wounds consists of the following stages involving mixing the primary material and auxiliary in the pre-set amounts by chemical mixture and preparation of the mixture at the stage of latex, and cooling to form a solid piece, packaging and sterilising.

EFFECT: material is degradable in the body and promotes osteal wound healing.

7 cl, 4 tbl, 9 ex

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injection is added to the lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin monomer at a concentration of 11 mg/ml and urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. At that the dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective the prevention of bleeding caused by the use of streptokinase, prior to surgical interferences.

1 ex, 2 dwg

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injections is added to lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin-monomer at a concentration of 11 mg/ml and the urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. The dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective for prevention of bleeding caused by the use of dabigatran etexilate in the experiment.

2 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition.

EFFECT: group of inventions relates to improvement of octreotide bioavailability.

100 cl, 39 ex, 10 dwg, 45 tbl

FIELD: medicine.

SUBSTANCE: medication based on tripeptide Ac-Ala-Phe-Lys-Pip·AcOH or its pharmaceutically acceptable salts is applied. The claimed medication can be made in the form of a solution, gel, plate or sponge.

EFFECT: application of the said medication makes it possible to considerably reduce the volume of haemorrhage and reduce the time of bleeding stopping due to high anti-plasmin activity of the tripeptide Ac-Ala-Phe-Lys-Pip·AcOH with the absence of side effects.

2 cl, 8 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: wound canal is packed with a preparation of recovered oxygenated cellulose. Thereafter in an entrance wound, the preparation is exposed to 2 cycles of cryotherapy with liquid nitrogen at a temperature of minus 196°C for 1-2 minutes until an ice crust is formed on the wound surface.

EFFECT: method provides excluding the possibility of bleeding and bile flowing from an inner surface of stab wounds, reducing a risk of recurrent bleedings, formation of liver haematomas postoperatively.

3 dwg, 2 tbl, 2 ex

Haemostatic agent // 2545991

FIELD: medicine.

SUBSTANCE: invention relates to medicine and veterinary and is intended for the acceleration of stopping bleeding in case of injury to blood vessels in traumas and wounds. A haemostatic agent contains 3-20 wt % of a polysaccharide, where the polysaccharide is represented by chitosan and/or starch, 0.1-2 wt % of calcium chloride and a 0.5-5% water solution of succinic or hydrochloric acid - the remaining part.

EFFECT: accelerating the initiation of the thrombus-forming process and enhancement of the regenerative ability of tissues in the area of wounds of different aetiology.

1 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutically acceptable salts specified in a group consisting of sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, arginine salt, lysine salt, methanamine salt, dimethylamine salt, trimethylamine salt, ethylamine salt, diethylaminte salt, triethylamine salt, ethanolamine salt, piperazine salt, dibenzylethylene diamine salt, methyl glucamine salt, tromethamine salt, quaternary tetramethylammonium salt, quaternary tetraethylammonium salt and choline salt, bicyclosubstituted azopyrazole derivatives of general formula

.

The invention also refers to a method for preparing them, a pharmaceutical composition containing them, and using them as a therapeutic agent, particularly as thrombopoietin (TPO) mimetics, using them as TPO agonists. In general formula (I), Het is specified in a group consisting of phenyl, furanyl and thienyl; each R1, R2, R3 andR4 are independently specified in a group consisting of hydrogen and alkyl; n is equal to 0, 1 or 2.

EFFECT: improving the pharmokinetic properties of the compound of formula (I) ensured by better solubility.

19 cl, 1 tbl, 25 ex

FIELD: biotechnology.

SUBSTANCE: bispecific antibody is proposed, that binds to both the blood coagulation factor IX/activated blood coagulation factor IX and with the blood coagulation factor X, and functionally replaces the function of blood coagulation factor VIII. The nucleic acid is considered, encoding the antibody of the invention, a vector, a cell and a method of producing the antibody, and also a pharmaceutical composition and a kit for use in the method of preventing and/or treating bleeding or diseases associated with or caused by bleeding.

EFFECT: invention may find further application in the treatment of diseases associated with impaired blood clotting.

16 cl, 2 ex, 6 dwg

FIELD: chemistry.

SUBSTANCE: claimed is bispecific antibody, which is bound with both blood coagulation factor IX/activated blood coagulation factor IX and with blood coagulation factor X and functionally replaced function of blood coagulation factor VIII. Described are nucleic acid, coding antibody by invention, vector, cell and method of obtaining antibody, as well as pharmaceutical composition and set for application in method of prevention and/or treatment of bleeding or diseases, associated with or induced by bleeding.

EFFECT: invention can be applied in therapy of diseases, associated with blood coagulation disorders.

16 cl, 2 ex, 6 dwg

FIELD: medicine.

SUBSTANCE: invention refers to molecular biology, medicine, biochemistry and gene engineering. Presented is a human growth hormone derivative containing an additional disulphide bond as compared to hGh defined by SEQ ID No. 1, wherein the derivative contains at least one pair of mutations described by H21C/M170C, D26/V102C, D26/Y103C, F54C/Y143C, F54C/S144C, S55C/Y143C, S57C/Y143C, I58C/Q141C, I58C/Y143C, I58C/S144C, P59C/Q137C, S71C/S132C, L81C/Y143C, Q84C/Y143C, S85C/Y143C, S85C/S144C, F92C/T148C and/or R94C/D107C in SEQ ID No. 1, and possesses the activity of the human growth hormone, as well as a method for preparing this derivative, using it, a method of treating and a pharmaceutical composition.

EFFECT: invention possesses high stability and resistance to proteolytic degradation as a consequence of the introduction of cysteine residues.

18 cl, 3 dwg, 6 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of biochemistry, in particular to recombinant factor VIII, which contains one or more mutations, resulting in an increased stability of both the factor VIII and factor VIIIa, as well as to a pharmaceutical composition for treating haemophilia containing it. Also described is a molecule of nucleic acid, coding the said recombinant factor VIII, and an expression vector and host-cells, containing the said molecule of nucleic acid. The invention also relates to a method of obtaining the said factor VIII, as well as to its application in the method of treating haemophilia A in an animal.

EFFECT: invention makes it possible to obtain a biologically active factor VIII with an increased stability.

50 cl, 12 dwg, 5 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to medicine, namely to pharmacology and describes a histidine-free pharmaceutical composition containing high-purity factor VIII; arginine and saccharose, a surfactant for the prevention or at least the inhibition of a surface adsorption of factor VIII; 0.5 to 10 mM calcium chloride for the specific stabilisation of factor VIII, and sodium citrate or maleic acid as a pH buffer.

EFFECT: invention provides the protective function for preserve high-yield factor VIII over the whole cycle of pharmaceutical processing, long storage and end recovery and administration into the patient.

18 cl, 16 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention represents method of stabilisation of liquid solution of coagulation and/or clotting factors for storing in frozen state, which contains: providing liquid solution of coagulation and/or clotting factor, where said solution has concentration NaCl and/or KCl, at least, 100 mM; addition of carbohydrate to said solution until said solution reaches in freezing temperature of vitrifying -56°C or higher; and freezing of said solution for storage.

EFFECT: invention ensures stabilisation of liquid solution of coagulation or clotting factors for storing in frozen state.

20 cl, 1 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and describes a method for recovery of factor VIII from human blood plasma not identified by related analysis of hepatitis and HIV1/2 viruses consisting in sequential cryoprecipitation, dissolution in an aqueous solution of heparin and solubilisation of a cryoprecipitate, sorption of a prothrombin-converting complex factor by aluminium hydrate, removal of fibrinogen, fibronectin and associated protein by polyethylene glycol-4000, viral inactivation with solvent detergents and preliminary filtration, anion-exchange chromatography, preferentially with EDM-TMAE Fractogel, with elution by a sodium chloride buffer, stabilisation by albumine solution, sterile filtration in membrane filters of pore diameter 0.22 mcm, bottling (200-300 IU/bottle), lyophilisation and second thermal viral inactivation with purification using the aqueous solution of unfractionated heparin of the concentrations equal to 5-100 international units (IU)/ml, preferentially 10-25 IU/ml, polyethylene glycol-4000 in the final concentration 3.5% and acidification of the medium, preferentially to pH 6.6, strong TMAE anion exchangers.

EFFECT: method substantially provides higher effectiveness of purification and specific activity of factor VIII.

1 tbl, 4 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns area of molecular biology and biochemistry, and can be used in medicine. There is offered mutein conjugate of the blood coagulation factor VIII (FVIII) wherein a residue not being cysteine in position 41, 129, 377, 388, 468, 491, 556, 1804, 1808, 1810, 1812, 1813, 1815 and/or 2118 is substituted by a cysteine residue with polyethylene glycol (PEG) where a PEG molecule is bound with a polypeptide in a mutant cysteine residue.

EFFECT: improved pharmacokinetic properties of the FVIII as an ingredient of the conjugate under the invention with preserved a procoagulant factor activity allows presenting new FVIII PEG-muteins for producing of a pharmaceutical compositions for treating hemophilia.

12 cl, 38 dwg, 8 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared invention refers to chemical-pharmaceutical industry. A method involves the following stages: preparing a solution of von Willebrand factor or von Willebrand factor/factor VIII complex which contains VWF in concentration up to 12 IU VWF:RCoAui and has the von Willebrand factor/factor VIII ratio equal to 0.4 or more; nanofiltering through a filter of pore size less than 35 nanometres at pressure less than or equal to 0.5 bar and in the presence of 0.05 to 0.2 M of calcium ions.

EFFECT: development of the effective method for producing concentrated von Willebrand factor or factor VIII/von Willebrand factor complex to be applied for treating hemophilia And or von Willebrand disease.

11 cl, 8 ex, 6 tbl, 1 dwg

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology and specifically to obtaining versions of glycoprotein IV alpha polypeptide of human thrombocytes (GPIbalpha) and can be used in medicine to treat vascular disorders. Using a recombinant technique, a polypeptide is obtained, which contains substitutes in SEQ ID NO:2 selected from: Y276F K237V C65S; K237V C65S; Y276F C65S; or Y276F Y278F Y279F K237V C65S. The obtained polypeptide is used to inhibit bonding of leucocytes to biological tissue or for treating disorders associated with activation of thrombocytes.

EFFECT: invention enables to obtain GPIbalpha polypeptide which bonds with von Willebrand factor with affinity which is at least 10 times higher than in natural GPIbα polypeptide, and also has low affinity for bonding with alpha-thrombin, lower aggregation and/or high resistance to proteolysis relative the polypeptide with SEQ ID NO:2.

41 cl, 3 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: invention claims compositions which can include one or several mammary gland tumour proteins, their immunogenic parts or polynucleotides encoding such parts. Alternatively the therapeutic composition can include antigen-presenting cell expressing mammary gland tumour protein, or T-cell specific to cells expressing such protein. These compositions can be applied in prevention and treatment of such diseases as mammary gland cancer. Invention also claims diagnostic methods based on determination of mammary gland tumour protein or mRNA encoding such protein in sample.

EFFECT: use of peptides obtained from protein expressed from mammary gland by tumour in diagnostics and therapy of mammary gland cancer.

37 cl, 6 ex, 1 dwg

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to method of human blood coagulation VIII factor production and related product. Method includes blood serum as cryoprecipitate, heparine added, PEG-4000, centrifugation, supernatant is added with tributyl phosphate and Twin-80, repeated centrifugation, sediment washed with sodium chloride, then it is dissolved in tris-HCl buffer with additives, let through column filled with gel and attached antibodies to Willebrand's factor, factor VIII elution, dialysis. Produced concentrate does not contain Willebrand's factor and has activity not less than 300 ME/mg of protein with purity not less 98% and contains albumin of concentration of 0.1%. Product is lyophilized with further processing.

EFFECT: product does not display any toxicity and cause allergic reaction.

6 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine. Described are: fibrin matrix, method of its obtaining and method of processing or prevention of defect on wet tissue of object requiring processing. Described is application for hermetic sealing of defect in mucous membrane or other wet tissue.

EFFECT: fibrin matrix is efficient for sealing tissue leakages.

35 cl, 3 dwg, 1 tbl, 3 ex

Up!